SCHEMBL18214367

SCHEMBL18214367

COC1=CC(=O)OC(CCc2ccc(C(F)(F)F)cc2)C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.70
ALDH1A1 P00352 2/20 0.61
TDP1 Q9NUW8 1/20 0.61
DAO P14920 4/20 0.39
KDM1A O60341 1/20 0.38
MAPT P10636 1/20 0.38
MAOA P21397 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
HIF1A Q16665 1/20 0.38
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
MTNR1B P49286 1/20 0.36
MAOB P27338 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
KCNA5 P22460 1/20 0.35
KCNH2 Q12809 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5671273 0.86 CYP3A4 (0.76) CYP3A4ALDH1A1TDP1KDM1AMAPT
SCHEMBL5671269 0.86 CYP3A4 (0.76) CYP3A4ALDH1A1TDP1KDM1AMAPT
SCHEMBL20148117 0.84 CYP3A4 (0.78) CYP3A4ALDH1A1TDP1KDM1AMAPT
SCHEMBL18214339 0.84 CYP3A4 (0.78) CYP3A4ALDH1A1TDP1DAOKDM1A
SCHEMBL18214442 0.83 CYP3A4 (0.76) CYP3A4ALDH1A1TDP1KDM1AMAPT
SCHEMBL18214373 0.83 CYP3A4 (0.76) CYP3A4ALDH1A1TDP1KDM1AMAPT
SCHEMBL11308370 0.83 CYP3A4 (0.76) CYP3A4ALDH1A1TDP1KDM1AMAPT
Dihydrokawain SCHEMBL2743647 0.83 CYP3A4 (1.00) CYP3A4ALDH1A1TDP1KDM1AMAPT
Dihydrokawain SCHEMBL5672433 0.83 CYP3A4 (1.00) CYP3A4ALDH1A1TDP1KDM1AMAPT
SCHEMBL18214340 0.81 CYP3A4 (0.72) CYP3A4ALDH1A1TDP1DAOKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200255395-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF KUALITY HERBCEUTICS LLC (US) 2020-08-13 US disclosed
US-20180134679-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF KUALITY HERBCEUTICS LLC (US) 2018-05-17 US disclosed
WO-2016179587-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF KUALITY HERBCEUTICS LLC (US) 2016-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134679-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF NQO1, VHL, XIAP CYP3A4 2215/4885ALDH1A1 223/4885TDP1 1633/4885
US-20200255395-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF NQO1, VHL, XIAP CYP3A4 2215/4885ALDH1A1 223/4885TDP1 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.